Abstract:Purpose: To investigate the possibility of using radiofrequency hyperthermia (RFH) to enhance intratumoral therapeutic effect of liposomal doxorubicin on hepatocellular carcinoma (HCC) via an interventional molecular imaging approach. Materials and methods: For both in-vitro confirmation and in-vivo validation, Luciferase/ mCherry-labeled human HCC cells (HepG2) and mice subcutaneous hepatic cancer xenografts were treated by: (i) combination therapy of liposomal doxorubicin plus RFH at 42 degrees C; (ii) liposomal doxorubicin alone; (iii) RFH at 42 degrees C alone; (iv) phosphate buffered saline (PBS) as a control. For in-vitro confirmation, MTS assay, confocal microscopy, optical imaging and flow cytometry were used to evaluate and compare cell viabilities and apoptosis among different treatment groups. For in vivo validation, liposomal doxorubicin was directly injected into the tumor and RFH was performed subsequently under ultrasound imaging guidance. Changes of tumor sizes were quantified using ultrasound imaging and bioluminescence signal intensities after treatments were measured by optical imaging over 14 days, which were correlated with subsequent histology analysis. Results: Of in vitro experiments, MTS assay demonstrated the lowest cell proliferation in combination therapy group compared with the other three groups (25.0 +/- 5.6% vs 49.7 +/- 5.2% vs 94.2 +/- 3.9% vs 100%, respectively, P < 0.001). Flow cytometry showed the highest percentage of early a poptotic HepG2 cells in combination therapy compared to the other three groups (37.9 +/- 3.2% vs 32.2 +/- 1.7% vs 2.9 +/- 1.7% vs 1.8 +/- 0.7%, respectively, P < 0.001). Of in vivo experiments, optical imaging demonstrated a significantly decreased bioluminescence signal intensities in the combination therapy group, compared with the other three groups (0.53 +/- 0.10 VS 1.4 +/- 0.5 VS 2.8 +/- 0.8 VS 3.0 +/- 0.3, P < 0.05). Ultrasound images showed the smallest tumor volumes of the combination therapy group, in comparison to other control groups (0.7 +/- 0.1 VS 1.8 +/- 0.4 VS 3.0 +/- 0.8 VS 3.3 +/- 0.3, P < 0.05). Both histologic correlation confirmed imaging findings. Conclusion: RFH can enhance intratumoral therapy with liposomal doxorubicin for HCC, which is effectively monitored by ultrasound imaging and optical imaging techniques. This concept may provide new avenues for eradicating the residual tumor cells when combining RFA with interventional molecular imaging guided direct intratumoral chemotherapy of HCC.

Cellular Uptake Study on Radiolabeled Telomerase-targeted Small Interference RNA in Hepatocarcinoma Cells

Preparation and Tumor Cell Uptake of Sirna Probe Radiolabeled with Technetium-99m Targeting on Htert Gene

[In-Vivo Tumor Imaging by Radiolabeled RNA Probe Targeting Telomerase].

In-vitro Inhibitory Activity and In-vivo Biodistribution of ~(99)Tc~m Radiolabeled Small Interference RNA

Noninvasive Visualization Of Rna Delivery With Tc-99m-Radiolabeled Small Interference Rna In Tumor Xenografts

In-vitro Inhibitory Activity and In-Vivo Biodistribution of "9"9tc"m Radiolabeled Small Interference RNA

Molecular Imaging and Pharmacokinetics of (99m) Tc-hTERT Antisense Oligonucleotide As a Potential Tumor Imaging Probe.

A novel molecular probe:experimental study in vivo in nude mice bearing tumor

In Vitro Research on MicroRNA-155 Targeted Radiolabeled Oligonucleotide in Breast Cancer Cells

[Uptake Kinetics of Htert Antisense Molecular Probe by Cells and Its Biological Properities].

RNAi-hTERT Inhibition Hepatocellular Carcinoma Cell Proliferation Via Decreasing Telomerase Activity

Inhibitory Effect of Sirna Targeted at Telomerase of Hepatocellular Carcinoma(hepg2)transfected by Lentivirus in Vitro

Noninvasive Imaging of C(Rgd)(2)-9r As A Potential Delivery Carrier for Transfection of Sirna in Malignant Tumors

Noninvasive Imaging of Human Telomerase Reverse Transcriptase (htert) Messenger Rna with (99)Mtc-Radiolabeled Antisense Probes in Malignant Tumors

Intratumoral Radiofrequency Hyperthermia-Enhanced Chemotherapy of Liposomal Doxorubicin on Hepatocellular Carcinoma.

Study on in vivo imaging of 99Tcm-hTERT mRNA as antisense molecular probe in breast cancer tumor-bearing nude mice

A Novel 99mTc-Labeled Molecular Probe for Tumor Angiogenesis Imaging in Hepatoma Xenografts Model:A Preliminary Study

A Novel Tc-99m-Labeled Molecular Probe For Tumor Angiogenesis Imaging In Hepatoma Xenografts Model: A Pilot Study

Study on Pharmacokinetics and Acute Toxicity of Human Telomerase Reverse Transcriptase Antisense Oligonucleotide Molecular Probe

Aggregation‐induced Emission (AIE) and Magnetic Resonance Imaging Characteristics for Targeted and Image‐guided siRNA Therapy of Hepatocellular Carcinoma

[Primary study on fluro [ 19F] berberine derivative for human hepatocellular carcinoma targetting in vitro].